来那度胺联合低剂量地塞米松(Rd)对比硼替佐米、美法仑、泼尼松(VMP)治疗老年初诊多发性骨髓瘤患者:两项前瞻性试验的比较
两项随机III期试验的VMP组(257例)和Rd组(222例)用于评估老年初治多发性骨髓瘤患者的治疗影响,随访60个月。VMP在入组至12个月显著降低疾病进展率,32个月后Rd组进展发生率更低;VMP组总生存率显著更高,调整潜在混杂因素后仍维持。两种方案毒性均可接受。
要点
- VMP在入组至12个月随访期间显著降低疾病进展率。
- 32个月后Rd组疾病进展发生率低于VMP组。
- VMP组总生存率显著更高,数据调整后仍维持。
核心结论
- VMP与显著降低的死亡风险相关。
- 本研究可能帮助医生做出更知情的治疗选择。
研究设计与样本
- 采用两项随机III期试验的VMP组(257例)和Rd组(222例),评估老年初治多发性骨髓瘤患者的治疗影响,随访60个月。
- 无进展生存期(PFS)为主要终点,总生存期(OS)为次要终点。
主要发现
- VMP在入组至12个月随访期间显著降低疾病进展率,12至32个月期间两种方案无差异。
- 32个月后,Rd治疗患者的疾病进展发生率更低。
- VMP组观察到统计学显著更高的OS率,调整潜在混杂因素后仍维持。
- 两种方案均显示可接受的毒性特征。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There are currently no direct head-to-head clinical trials evaluating bortezomib-melphalan-prednisone (VMP) versus lenalidomide and low-dose dexamethasone (Rd). VMP (257 cases) and Rd (222 cases) arms of two randomized phase III trials were employed to assess the treatment influence on outcome in untreated elderly MM patients. Progression free survival (PFS) and overall survival (OS) were the primary and secondary end-points, respectively, and were investigated according to treatments administered over a 60-months follow-up period. While VMP significantly reduced the disease progression rate between enrolment and 12 months of follow-up, no difference between the two schedules was found between 12 and 32 months. After 32 months, Rd-treated patients had a lower incidence of disease progression. A statistically significant higher OS rate was seen in the VMP arm, which was maintained after data adjustment for potential confounders. Both approaches showed acceptable toxicity profiles. The profound tumor reduction by VMP over Rd justifies the initial higher PFS rate in favor of the bortezomib schedule, while the Rd regimen overcomes this evident initial drawback in reducing the tumor burden by long-term drug administration, gaining a subsequent improved disease control. VMP is associated with a significant reduced risk of death. This study may help physicians make a more informed therapy choice.
引用
- Gentile M, Magarotto V, Offidani M, et al. Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials. Am J Hematol. 2017. PMID: 28006855. doi:10.1002/ajh.24621
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。